August 13, 2025 — Aptevo Therapeutics Inc. (Nasdaq:APVO) is reinforcing the strategic importance of its preclinical asset APVO442, an investigational CD3-engaging bispecific antibody designed to treat prostate cancer.
Built on Aptevo’s next-generation ADAPTIR-FLEX platform, APVO442 is engineered to selectively activate T cells within the PSMA-expressing tumor microenvironment, offering potential for precision targeting and reduced systemic toxicity. It utilizes the same CRIS-7-derived anti-CD3 binding domain as clinical candidate mipletamig but is specifically engineered for solid tumors, with lower binding affinity and a monovalent format.
Preclinical data show that APVO442 effectively localizes to PSMA-expressing prostate tumors, triggering a targeted immune response while potentially sparing healthy tissue. According to Marvin White, President and CEO of Aptevo, the company is confident in the strength of its CD3-based bispecific approach.
Prostate cancer is the second most common cancer in men, with over 300,000 new cases annually in the U.S. The global treatment market is projected to reach $24 billion within the next decade. APVO442 is currently in preclinical studies.
Miriam Weber Miller, Head of Investor Relations & Corporate Communications, can be reached at IR@apvo.com or Millerm@apvo.com, or by phone at 206-859-6628.
Source: Aptevo Therapeutics
